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When considering implementing DICE methodology, the speed at which the 
chosen software can read specifying tables and process consequences of events, 
and the practical implications of this, should be carefully evaluated. 
Evidence from TA494 suggests that applying DICE methodology for a DES in 
Microsoft Excel® may lead to impractically long run times for a NICE STA model. 
To assess the suitability of a Discretely Integrated Condition Event (DICE) 
approach to discrete event simulation (DES) modelling in Microsoft Excel for a 
company submission to the National Institute for Health and Care Excellence 






• We reviewed published comment from the appraisal committee from NICE TA494 on 
the company’s approach to pharmacoeconomic modelling, and the use of DICE 
simulation in particular.
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Methods
DICE
• In March 2016, DICE simulation was proposed as a unifying approach to 
pharmacoeconomic analysis, designed to meet the modelling requirements of such 
analyses.1 
• Within a DICE simulation, the analyst structures a pharmacoeconomic decision 
problem as a set of conditions (aspects that persist over time) and events (aspects 
that occur at a point in time) within spreadsheet tables that specify condition values 
and event consequences.1 Model execution involves the selected software reading 
the specifying tables and processing the consequences of each event when it 
occurs. The occurrence of events is implemented using straightforward background 
code that establishes an event schedule and maintains it as events happen and 
conditions change.
• A key advertised benefit of DICE simulation is transparency and ease of stakeholder 
review. The specification of a disease process and its care pathway in terms of 
conditions and events within a spreadsheet is argued to facilitate validation, as the 
reviewer needs only to be familiar with spreadsheet format and not with a particular 
software programme or programming language.1
• While a range of cohort-level and individual-level model types typical to 
pharmacoeconomic evaluations could be specified as a DICE simulation, and a DICE 
simulation could be specified within a range of software options, the transparency 
benefits of DICE simulation may be particularly appealing to individual-level 
pharmacoeconomic models, and contemporary pharmacoeconomic models are very 
likely to be built in Microsoft Excel®
• An overwhelming majority of contemporary pharmacoeconomic models are 
built in Microsoft Excel®, as evidenced by a review of NICE STA 
documentation for STAs published between May 2016 and May 2017 that 
found 35 of the 36 company submissions that stated model software to have 
used Microsoft Excel®.2
• In individual-level models versus cohort level models in Microsoft Excel®, there 
is a greater call to specify model logic as “back-end” Visual Basic for 
Applications (VBA) logic versus “front-end” spreadsheet logic
• An overwhelming majority of contemporary pharmacoeconomic models are 
cohort-level models, as evidenced by the same review of STAs published 
between May 2016 and May 2017 finding 43 of the 48 submissions to be 
based on a pharmacoeconomic model specified solely at the cohort-level.2 As 
such, practicing health economic modelers build and review far more cohort-
level than individual-level models, and require and develop fewer practiced 
skills in the elements of VBA logic that are useful for individual-level models 
versus the subset of these required for cohort-level models (or, individual-level 
models specified as a DICE simulation) 
NICE TA494: Naltrexone–bupropion for managing overweight and obesity
• The decision problem required the NICE appraisal committee to consider whether 
naltrexone-bupropion (NB), within its licensed indication and in addition to diet and 
physical activity, would be a clinically effective and cost-effective strategy for NHS 
England, for the management of people with obesity or overweight with risk factors.3
• The company approach to modelling built on an existing systematic review and 
economic evaluation of drugs to treat obese patients in primary care in the UK from 
Ara et al.,4 produced as part of the UK National Institute for Health Research Health 
Technology Assessment programme.3
• An individual-level approach was considered better suited than a cohort-level 
approach to capture the chronic implications of both weight and weight-related health 
events in a heterogenous group of patients, by both Ara et al. and the company 
submission for TA494.3,4
• The key clinical effectiveness evidence for NB were from four multicenter, 
randomized, double-blinded, placebo-controlled studies. Data and assumptions 
about long-term effectiveness and natural history used in TA494 were underpinned 
by the work of Ara et al.3,4
• The ERG Report describes the ERG being able to “check formulae in the DICE 
sheet” but being “unable to examine the internal validity of the model according to its 
usual standards” and that this was mainly a “consequence of long model run times for 
one single deterministic analysis”.5
• The use of a DES model type was endorsed by the committee and ERG.6
• The Final Appraisal Determination states that a “revised model [using VBA directly] 
ran more efficiently”.5 This “revised model” was similar to the originally submitted 
model, but implemented directly in VBA, trading off the transparency benefit of DICE 
spreadsheet tabulation for increased speed of model execution. Base case model 
execution was approximately 200 times faster in the revised version of the model.
• The revised model was deemed appropriate for decision-making.6
• In TA494, the benefits of DICE simulation were clearly outweighed by its costs.
• The transparency benefits of DICE simulation, for both verification and validation, are 
more valuable for less typical pharmacoeconomic model types and 
pharmacoeconomic model types that require more underlying code logic versus 
spreadsheet logic, e.g. individual-level modelling approaches such as DES
• However, the cost of DICE simulation in terms of increased run time is pronounced in 
such modelling approaches. The difference in model execution speed between the 
originally submitted DICE implementation and revised implementation in TA494 is 
explained by the relative speed of processing calculations completely within VBA 
logic versus through interactions between VBA and spreadsheets in Microsoft Excel®.
• On the limitation of model execution speed, the introductory publication for DICE says 
only the following: “Very complex analyses requiring many profiles and scenarios 
may tax spreadsheet calculations but that is a limitation of the software not of DICE. 
Given its flexibility and transparency, DICE should be considered a good option 
whenever a decision-analytic model is required.” 1
• The pharmacoeconomic model underpinning TA494 was not very complex. 
That it analysed cost-effectiveness at the patient-level could be considered a 
complexity, but if so it is one that we would hope a unifying approach for 
pharmacoeconomic analysis would be able to comfortably handle. 
• The proponent of DICE may bear no responsibility for the processing speed 
limitations of spreadsheet calculation in Microsoft Excel®, but the model 
execution speed when using DICE simulation in software that is almost 
ubiquitous in contemporary pharmacoeconomic modelling is certainly relevant 
when considering DICE as an option for decision analytic modelling.
• Our findings are consistent with conclusions from as separate study validating 
DICE against an equivalent code-based approach, published in July 2017.7
Results
• The Appraisal Consultation Document reports the Evidence Review Group (ERG) 
and company experiencing “extremely slow run times” and the committee concluded 
that “an alternative approach to implementing the DES model would be more 
practical for decision-making”. 
DICE
Implementation
~4 patients per minute
VBA
Implementation
~800 patients per minute
